Imidazoquinoline compounds
View Patent ↗Disclosed herein are a compound of formula (I) and pharmaceutically acceptable salts thereof, processes for preparing the same, pharmaceutical compositions containing the same, and methods of using the same.
1. A compound of formula (I) and/or pharmaceutically acceptable salts thereof:
2. The compound according to claim 1 , wherein said compound of formula (I) is in the form of a free base.
3. The compound according to claim 1 , wherein said compound of formula (I) is in the form of a pharmaceutically acceptable salt.
4. The compound according to claim 1 , wherein said compound of formula (I) is Form A.
5. A pharmaceutical composition comprising a compound according to claim 1 and/or pharmaceutically acceptable salts thereof and at least one component chosen from pharmaceutically acceptable adjuvants, pharmaceutically acceptable diluents, and pharmaceutically acceptable carriers.
6. The pharmaceutical composition according to claim 5 , in a form for topical administration, systemic administration, parenteral administration, subcutaneous administration, rectal administration, or transdermal administration.
7. The pharmaceutical composition according to claim 5 , further comprising at least one additional therapeutic agent.
8. The pharmaceutical composition according to claim 7 , wherein said at least one additional therapeutic agent is chosen from:
a) PDE4 inhibitors;
b) β-adrenoceptor agonists;
c) muscarinic receptor antagonists;
d) modulators of chemokine receptor function;
e) inhibitors of kinase function;
f) non-steroidal glucocorticoid receptor agonists;
g) steroidal glucocorticoid receptor agonists;
h) protease inhibitors; and
i) antiproliferative agents.
9. A process for the preparation of a compound according to claim 1 comprising:
a) reacting a compound of formula (II) or a salt thereof:
wherein Lg is a leaving group chosen from halo, mesylate, triflate, besylate, and tosylate,
with diethylamine to a form compound of formula (I); or
b) coupling a compound of formula (III) or a salt thereof:
with 2-(diethylamino)acetic acid or a salt thereof to form a compound of formula (I); and
c) optionally forming a pharmaceutically acceptable salt of the compound of formula (I).
10. A kit comprising, as at least one first active ingredient, a compound of formula (I) and/or a pharmaceutically acceptable salt thereof:
at least one second active ingredient chosen from:
a) PDE4 inhibitors;
b) β-adrenoceptor agonists;
c) muscarinic receptor antagonists;
d) modulators of chemokine receptor function;
e) inhibitors of kinase function;
f) non-steroidal glucocorticoid receptor agonists;
g) steroidal glucocorticoid receptor agonists;
h) protease inhibitors; and
i) antiproliferative agents,
and instructions for the simultaneous, sequential or separate administration of the active ingredients to a patient in need thereof.
11. A compound chosen from a compound of formula (II) and/or salts thereof:
wherein Lg is a leaving group chosen from halo, mesylate, triflate, besylate, and tosylate.
12. A compound chosen from a compound of formula (III) and/or salts thereof: